



Anticoagulation UK

NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE GUIDANCE

The Management of Atrial Fibrillation

<http://www.nice.org.uk/guidance/CG180>

Atrial Fibrillation Quality Standard

www.nice.org.uk/guidance/qs93

Venous thromboembolism: reducing the risk: Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital

<http://www.nice.org.uk/guidance/CG92>

Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing

<http://www.nice.org.uk/guidance/CG144>

Quality Standard for diagnosis and management of thromboembolic diseases

<http://www.nice.org.uk/quality/QS29>

NICE Pathways – Mapping the guidance

This online tool provides quick and easy access, topic by topic, to the range of guidance from NICE, including quality standards, technology appraisals, clinical, public health and social care guidelines and NICE implementation tools.

<http://pathways.nice.org.uk/>

Atrial fibrillation and heart valve disease: self monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor)

<http://www.nice.org.uk/guidance/dg14>

Guidance for anticoagulants

Apixaban

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults

<http://www.nice.org.uk/guidance/TA245>

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation

<http://www.nice.org.uk/guidance/TA275>

Apixaban for the treatment and secondary prevention of deep vein thrombosis and /or pulmonary embolism

<http://www.nice.org.uk/guidance/TA341>

Dabigatran

Dabigatran Etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults

<http://www.nice.org.uk/guidance/TA157>

Dabigatran Etexilate for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation

<http://www.nice.org.uk/guidance/TA249>

Dabigatran Etexilate for the treatment and secondary prevention of deep vein thrombosis and /or pulmonary embolism

<http://www.nice.org.uk/guidance/TA327>

Dabigatran Etexilate Reversal Agent Idarucizumab

<https://www.nice.org.uk/advice/esnm73/chapter/Key-points-from-the-evidence>

https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1178_16_idarucizumab_Praxbind/idarucizumab_Praxbind

Edoxaban

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

<http://www.nice.org.uk/guidance/TA355>

Edoxaban for treating and preventing deep vein thrombosis and pulmonary embolism

<http://www.nice.org.uk/guidance/TA354>

Rivaroxaban

Rivaroxaban for the prevention of venous thromboembolism after hip or knee replacement surgery in adults

<http://www.nice.org.uk/guidance/TA170>

Rivaroxaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation

<http://www.nice.org.uk/guidance/TA256>

Rivaroxaban for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism after a diagnosis of acute deep vein thrombosis in adults

<http://www.nice.org.uk/guidance/TA261>

Rivaroxaban treatment of acute symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis and the prevention of recurrent VTE events

<http://www.nice.org.uk/guidance/TA561>

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

<http://www.nice.org.uk/guidance/TA335>

SCOTTISH MEDICINES CONSORTIUM ADVICE

SMC advice relating to Apixaban, Dabigatran, Edoxaban and Rivaroxaban and their indications can be found in the SMC Advice Directory

<http://www.scottishmedicines.org.uk/Home>

OTHER GUIDELINES - DEVICES

The geko device for reducing the risk of venous thromboembolism

The Geko device looks like a small wristwatch that is attached below the knee. It stimulates the muscles in the leg and foot and may help to reduce the risk of blood clots forming. NICE has said that the Geko can be used for people in whom it is not possible to use other methods of preventing blood clots.

NICE medical technology guidance (MTG19) Published June 2014

[Anticoagulation UK, PO Box 405, Bromley, BR2 9WP](#)

[Email: info@anticoagulationuk.org](mailto:info@anticoagulationuk.org)